Literature DB >> 20393876

A new second-line sequential regimen for Helicobacter pylori eradication based on levofloxacin: a pilot study.

C Krystallis1, D Kamberoglou, D Pistiolas, C Anifanti, A Koutsoumbas, V Doulgeroglou, V Tzias.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20393876     DOI： 10.1007/s10620-010-1199-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  7 in total

1.  Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection.

Authors:  D Y Graham; S Abudayyeh; H M T El-Zimaity; J Hoffman; R Reddy; A R Opekun
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

2.  Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.

Authors:  Edoardo G Giannini; Claudio Bilardi; Pietro Dulbecco; Mario Mamone; Maria L Santi; Roberto Testa; Carlo Mansi; Vincenzo Savarino
Journal:  J Clin Gastroenterol       Date:  2006-07       Impact factor: 3.062

3.  Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.

Authors:  Javier P Gisbert; Fernando Bermejo; Manuel Castro-Fernández; Angeles Pérez-Aisa; Miguel Fernández-Bermejo; Albert Tomas; José Barrio; Felipe Bory; Pedro Almela; Pilar Sánchez-Pobre; Angel Cosme; Vicente Ortiz; Pilar Niño; Sam Khorrami; Luis-Miguel Benito; Jose-Antonio Carneros; Eloisa Lamas; Inés Modolell; Alejandro Franco; Juan Ortuño; Luis Rodrigo; Fernando García-Durán; Elena O'Callaghan; Julio Ponce; María-Paz Valer; Xavier Calvet
Journal:  Am J Gastroenterol       Date:  2007-08-31       Impact factor: 10.864

4.  Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication.

Authors:  Abdallah Said Essa; Jennifer Rosenthal Kramer; David Y Graham; Gerhard Treiber
Journal:  Helicobacter       Date:  2009-04       Impact factor: 5.753

5.  The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey.

Authors:  Ahmet Aydin; Nevin Oruc; Ilker Turan; Omer Ozutemiz; Muge Tuncyurek; Ahmet Musoglu
Journal:  Helicobacter       Date:  2009-12       Impact factor: 5.753

6.  Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.

Authors:  Richard J Saad; Philip Schoenfeld; Hyungjin Myra Kim; William D Chey
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

7.  Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment.

Authors:  Nadim S Jafri; Carlton A Hornung; Colin W Howden
Journal:  Ann Intern Med       Date:  2008-05-19       Impact factor: 25.391
  7 in total
  2 in total

1.  Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.

Authors:  Sotirios D Georgopoulos; Vasilios Papastergiou; Stylianos Karatapanis
Journal:  Gastroenterol Res Pract       Date:  2012-06-19       Impact factor: 2.260

2.  Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial.

Authors:  Daniela Munteanu; Ohad Etzion; Gil Ben-Yakov; Daniel Halperin; Leslie Eidelman; Doron Schwartz; Victor Novack; Naim Abufreha; Pavel Krugliak; Alexander Rozenthal; Nava Gaspar; Alexander Moshkalo; Vitaly Dizingof; Alexander Fich
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.